Kalemia during combined therapy with an angiotensin converting enzyme inhibitor and a potassium-sparing diuretic.
Both angiotensin converting enzyme (ACE) inhibitors and potassium-sparing diuretics tend to increase serum potassium levels. This retrospective study was undertaken to assess whether these two types of agents can nevertheless be combined safely. Twelve hypertensive patients were treated for 1-70 months (mean = 17) with an ACE inhibitor together with a potassium-sparing diuretic (spironolactone, n = 10; amiloride, n = 2). In addition, eight patients also took a thiazide or a loop diuretic. Nine patients had a normal and three a slightly impaired renal function. No clinically relevant hyperkalemia was observed during the course of the study. These data suggest that it is not impossible to combine an ACE inhibitor with a potassium-sparing diuretic, as long as renal function is normal and serum potassium concentration is monitored closely.
Mooser
V
V
Division of Hypertension, University Hospital, Lausanne, Switzerland.
Waeber
G
G
Bidiville
J
J
Waeber
B
B
Nussberger
J
J
Brunner
H R
HR
D000328:Adult; D002216:Captopril / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000627:therapeutic use*; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D011188:Potassium / Q000097:blood*; D013148:Spironolactone / Q000627:therapeutic use*
D013148:Spironolactone; D004656:Enalapril; D005665:Furosemide; D002216:Captopril; D003404:Creatinine; D011188:Potassium